申请人:Hoffmann-La Roche Inc.
公开号:US05955495A1
公开(公告)日:1999-09-21
The invention is concerned with the use of compounds of the general formula ##STR1## wherein R.sup.1 -R.sup.4 signify hydrogen, halogen, lower-alkyl, lower-alkoxy, aryl, benzyloxy, lower-alkoxy-lower-alkyl, lower-alkyl-sulphanyl, lower-alkyl-sulphanyl-lower-alkyl or R.sup.1 and R.sup.2 together signify the group --O--(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.2 --O-- and R.sup.5 signifies hydrogen or hydroxy, as well as their pharmaceutically acceptable salts in the control or prevention of illnesses or disorders of the central nervous system such as migraine, schizophrenia, anxiety states, sleep disorders, anorexia, Alzheimer's disease, addictions (alcohol, nicotine, benzodiazepine, cocaine, etc.), as well as disorders which result from damage to the head/brain or to the spinal column/bone marrow and, respectively, for the production of corresponding medicaments.
该发明涉及使用一般公式为##STR1##的化合物,其中R.sup.1 -R.sup.4表示氢、卤素、较低烷基、较低烷氧基、芳基、苄氧基、较低烷氧基-较低烷基、较低烷基硫醚基、较低烷基硫醚基-较低烷基,或R.sup.1和R.sup.2一起表示--O--(CH.sub.2).sub.2 --或--(CH.sub.2).sub.2 --O--,R.sup.5表示氢或羟基,以及它们在控制或预防中枢神经系统疾病或紊乱(如偏头痛、精神分裂症、焦虑状态、睡眠障碍、厌食症、阿尔茨海默病、成瘾(酒精、尼古丁、苯二氮卓类、可卡因等)以及由头部/脑部或脊柱/骨髓损伤引起的紊乱)的药用可接受盐,以及用于生产相应药物。